Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hutchmed China Ltd ADR (NQ: HCM )

17.38 -0.27 (-1.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hutchmed China Ltd ADR

< Previous 1 2 3 4 5 6 7 8 Next >
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
From Prenetics Limited
Via GlobeNewswire
Hutchmed Plans Strategic Focus Shift On Late-Stage Programs, Details Not Disclosed
Via Benzinga
HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer
Via Benzinga
Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo. 
Via Benzinga
Deutsche Bank ADR Investor Conference: Presentations Now Available for On-Demand Viewing
Company Executives Shared Vision and Answered Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Miniso Group, Monday.com And Other Big Gainers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
From HUTCHMED (China) Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
360 DigiTech, HUTCHMED And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study
HUTCHMED (China) Limited (NASDAQ: HCM) announced initial results from FRUTIGA Phase 3 trial of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for the week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday morning! 
Via InvestorPlace
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2022
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Applied Genetic Techs (NASDAQ:AGTC) shares moved upwards by 62.0% to $0.39 during Monday's pre-market session. The company's market cap stands at $26.3 million. 
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the... 
Via Benzinga
Nikola, Super Micro Computer And Other Big Losers From Monday
U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Groupon, Spectrum Brands, Adobe And Other Big Losers From Thursday
U.S. stocks closed lower with the Nasdaq 100 dropping around 200 points on Thursday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
7 Chinese Stocks to Sell While You Still Can
These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure 
Via InvestorPlace
Week in Review: Hansoh In-licenses Endometriosis/Fibroid Therapy in $170 Million Deal
Other funding deals for drug discovery, R&D, gene editing. 
Via Talk Markets
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Goldman Sachs Maintains Neutral Rating for HUTCHMED: Here's What You Need To Know
  Goldman Sachs has decided to maintain its Neutral rating of HUTCHMED (China) (NASDAQ:HCM) and raise its price target from $14.00 to $16.00. Shares of HUTCHMED (China) are trading down 5.74% over the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.